Outcome of a conservative approach in severe ulcerative colitis
- PMID: 14971812
- DOI: 10.1016/j.dld.2003.04.001
Outcome of a conservative approach in severe ulcerative colitis
Abstract
Background: Severe ulcerative colitis is potentially life threatening even though a policy of intensive medical management and early colectomy in recent years reduced mortality to almost zero. However, colectomy, with or without ileal-anal anastomosis, has its own problems (morbidity, pouchitis, cuffitis) and no reliable prognostic index of surgical outcome has been developed. Intravenous steroids are still the mainstay of medical therapy but their maximal duration before stating a 'treatment failure' has not been defined.
Aim of the study: To evaluate the effectiveness, safety and outcome of an intensive medical approach in a series of patients with severe ulcerative colitis.
Patients and methods: One hundred and forty-nine episodes of severe ulcerative colitis in 115 patients admitted to a Gastroenterology Unit in a 7-year period were retrospectively evaluated. Intravenous glucocorticosteroids--methylprednisolone 1 mg/kg/day--and topical steroids were administered, and supportive treatments with intensive monitoring were extended to all the patients. Second-line strategies for steroid-refractoriness were prolonged glucocorticosteroids treatment, oral ciclosporin, infliximab or surgery.
Results: The median number of Truelove criteria at admission was 3 (range 2-5), median CRP 34 mg/l (range 10-196). Median follow-up after discharge was 49 months. In 84 (57%) episodes an early response was noted, while 65 (43%) did not respond within 10 days to the standard steroid treatment. In the non-responders group, 28 patients went into remission with a prolonged steroid treatment (slow responders); 15 patients were treated with ciclosporin (eight responders) and 6 with infliximab (four responders). A total of 24 colectomies was performed in this group of patients (in 21 cases within 30 days from admission). Slow responders showed lower albumin levels (P = 0.02), higher cumulative dose of glucocorticosteroids in the year prior to admission (P = 0.02) and higher age (P = 0.03), in comparison with early responders. Major complications were noted in four episodes which responded to medical treatment. Disease-related mortality was zero.
Conclusions: Medical treatment and use of second-line therapies were effective in the present series of patients. A group of slow responders has been identified and, if an intensive medical monitoring is guaranteed, steroids can be safely prolonged after the first 10 days of treatment. Cumulatively, about 80% of the patients responded to short-term medical treatment, only 5% of the patients underwent colectomy in the follow-up period. Major adverse events were recorded in four patients, who had recovered completely after adequate medical treatment.
Comment in
-
Conservative approach to severe ulcerative colitis.Dig Liver Dis. 2004 Jan;36(1):4-6. doi: 10.1016/j.dld.2003.10.002. Dig Liver Dis. 2004. PMID: 14971809 No abstract available.
Similar articles
-
Colectomy rate in acute severe ulcerative colitis in the infliximab era.Dig Liver Dis. 2008 Oct;40(10):821-6. doi: 10.1016/j.dld.2008.03.014. Epub 2008 May 9. Dig Liver Dis. 2008. PMID: 18472316
-
Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis.Z Gastroenterol. 1998 Apr;36(4):287-93. Z Gastroenterol. 1998. PMID: 9612926
-
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.Aliment Pharmacol Ther. 2007 Aug 1;26(3):411-9. doi: 10.1111/j.1365-2036.2007.03383.x. Aliment Pharmacol Ther. 2007. PMID: 17635376
-
Current management of severe ulcerative colitis.Nat Clin Pract Gastroenterol Hepatol. 2007 Feb;4(2):92-101. doi: 10.1038/ncpgasthep0687. Nat Clin Pract Gastroenterol Hepatol. 2007. PMID: 17268544 Review.
-
Management of acute severe ulcerative colitis.Gut. 2011 Jan;60(1):130-3. doi: 10.1136/gut.2009.192765. Epub 2010 Oct 28. Gut. 2011. PMID: 21030524 Review.
Cited by
-
Severe ulcerative colitis: at what point should we define resistance to steroids?World J Gastroenterol. 2008 Sep 28;14(36):5504-7. doi: 10.3748/wjg.14.5504. World J Gastroenterol. 2008. PMID: 18810766 Free PMC article. Review.
-
Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.World J Gastroenterol. 2013 Jan 14;19(2):265-73. doi: 10.3748/wjg.v19.i2.265. World J Gastroenterol. 2013. PMID: 23345950 Free PMC article.
-
Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease.World J Gastroenterol. 2012 Oct 28;18(40):5771-8. doi: 10.3748/wjg.v18.i40.5771. World J Gastroenterol. 2012. PMID: 23155319 Free PMC article.
-
Drug therapy for ulcerative colitis.World J Gastroenterol. 2004 Aug 15;10(16):2311-7. doi: 10.3748/wjg.v10.i16.2311. World J Gastroenterol. 2004. PMID: 15285010 Free PMC article. Review.
-
Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital.Gastroenterol Hepatol (N Y). 2012 Apr;8(4):230-9. Gastroenterol Hepatol (N Y). 2012. PMID: 22723754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous